Sickle cell disease - preventing complications
This research was completed on 24 October 2003
|Project Leader||Professor John C Ellory ScD, DSc, Dr John S Gibson PhD, MA, BA, VetMB, MRCVS and Dr Sarah E Ball DM, FRCP, FRCPath, FRCPCH|
|Location||University Laboratory of Physiology, University of Oxford in conjunction with The Department of Physiology, University of London and Department of Haematology, St George's Hospital Medical School, Tooting, London.|
|Grant awarded||13 July 2000|
|Start date||25 October 2000|
|End date||24 October 2003|
We do not provide medical advice. If you would like more information about a condition or would like to talk to someone about your health, contact NHS Choices or speak to your GP. Please see our useful links page for some links to health information, organisations we are working with and other useful organisations. We hope you will find these useful. We are not responsible for the content of any of these sites.Sickle cell disease is a serious blood disorder for which there is no effective treatment. It affects a quarter of a million people per year, mainly in the Tropics, USA and the Caribbean but also in Northern Europe (due to migration) where it is one of the most common inherited diseases. In the UK, about 3,500 babies born every year will carry the sickle gene, and each year, over 200 of them will develop the disease. These patients have complications from sickle cell 'crises', (which can cause excruciating pain, stroke, bone, renal and lung disease) and also anaemia and infections. This project addresses how conditions in the circulation cause sickle cell crises to erupt and will investigate how the use of drugs can prevent these conditions arising.